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ABSTRACT
Cholestatic hepatitis is a rare presentation of thyrotoxicosis potentially confused as an adverse effect of antithyroid therapy. We
report a 37-year-old man with cholestatic hepatitis as an initial presentation of Graves’ disease. Diagnostic evaluation demonstrated
(i) elevated transaminases and alkaline phosphatase (R-factor value: 2.6), and marked cholestasis (total bilirubin: 17.3 mg/dL, direct
bilirubin: 9.4 mg/dL); (ii) negative hepatitis, viral, and autoimmune serologies; (iii) normal magnetic resonance chol-
angiopancreatography; (iv) liver biopsy with marked cholestasis and no fibrosis; (v) thyroid-stimulating hormone,0.01, fT4 (free
thyroxine): 1.5, fT4 (free triiodothyronine): 4.3 and positive thyroid-stimulating immunoglobulins. Radioiodine uptake scan
confirmed Graves’ disease. Clinical resolution was achieved with propranolol, prednisone, methimazole, and thyroidectomy.
INTRODUCTION
Clinical signs and symptoms of thyroid overactivity, goiter, and orbitopathy represent the cardinal features of Graves’ disease, the
leading cause of hyperthyroidism.1 A large cohort of patients with thyrotoxicosis reported elevated alkaline phosphatase (ALP) levels
in 29% of patients, but elevated transaminases and hyperbilirubinemia were less common.2 Direct catabolic effects of excessive
thyroid hormone on bone turnover and a bone origin of ALP may explain this discrepancy.2 Severe symptomatic cholestasis in
patients with Graves’ disease is rare, and etiology is often attributed to antithyroid therapy or occurring in the setting of thyroid
storm.3–5 Less common etiologies include concomitant autoimmune hepatitis or primary biliary cholangitis.6,7 We report a case of
cholestatic hepatitis in a 37-year-old man as an initial presentation of Graves’ disease, highlighting the importance of a thorough
diagnostic evaluation in a case that represents a diagnostic and therapeutic challenge.
CASE REPORT
A37-year-oldman complained of jaundice, pruritus, fatigue, diarrhea, and significant weight loss for 3months. His onlymedication
was oxycodone for chronic back pain after a car accident. He had no other medical problems and no family history of cholestatic or
other chronic liver disease. He denied alcohol, supplement, or excessive acetaminophen use. Physical examination demonstrated
scleral icterus and jaundice with no encephalopathy, exophthalmos, heart murmurs, hepatosplenomegaly, or stigmata of chronic
liver disease. His blood pressure was 122/82 mm Hg, and heart rate was 85 beats per minute. An electrocardiogram showed atrial
fibrillation. Initial laboratory test results showed a normal platelet count, international normalized ratio, albumin, and renal
function. A mixed pattern of elevated transaminases and ALP (R-factor value: 2.6) was noted with an aspartate aminotransferase
(AST) of 132 U/L, alanine aminotransferase (ALT) of 222 U/L, and ALP of 222 U/L. Significant cholestasis with a total bilirubin of
17.3 mg/dL and a direct fraction of 9.4 mg/dL was noted. No baseline liver chemistries were available. Hepatitis A, B, and C, human
immunodeficiency virus, cytomegalovirus, and Epstein Barr virus testing was negative.
ACG Case Rep J 2021;8:e00526. doi:10.14309/crj.0000000000000526. Published online: January 14, 2021
Correspondence: Zaid Imam, MBBS (zaidh.imam@gmail.com).
ACG Case Reports Journal / Volume 8 acgcasereports.com 1
Autoimmune workup was unremarkable with a negative anti-
nuclear antibody, antimitochondrial antibody testing, normal
immunoglobulins, and antismooth muscle antibody titer of 1:
20. A magnetic resonance cholangiopancreatography was
normal. Serum ferritin was 2,938 ng/mL, and ceruloplasmin
was normal. Hemochromatosis gene testing was heterozygous
for the H63D mutation.
Given the patient’s presenting symptoms, a thyroid profile
as obtained demonstrating suppressed thyroid-stimulating
hormone of ,0.01 mcIU/mL, fT4 (free thyroxine) of
1.5 ng/mL, and fT3 (free triiodothyronine) of 4.3 pg/mL.
Thyroid-stimulating immunoglobulins, thyroid-stimulating
hormone receptor antibodies, and antithyroid peroxidase
antibodies were positive. A radioiodine (RAI) uptake scan
demonstrated 90% diffuse uptake of radiotracer consistent
with Graves’ disease. To evaluate for alternative etiologies, a
transcutaneous liver biopsy was performed and was in-
consistent with autoimmune hepatitis and showed minimal
inflammation and marked cholestasis, with no fibrosis or ex-
cess iron deposition.
A diagnosis of severe thyrotoxicosis manifesting as cholestatic
hepatitis was established. Treatment was started with pro-
pranolol and low-dose methimazole. Minimal improvement
occurred in the first 2 days and oral prednisone (60 mg/daily)
was started on day 2 of hospitalization and tapered over 2
months. Although serum bilirubin fell by 57% to 5.3 mg/dL by
day 18, serum AST and ALT increased to 205 and 452 IU/L,
respectively. A surgical thyroidectomy was performed on day
18 of hospitalization, yielding a 44 g thyroid gland. Liver
chemistries markedly improved in 2 weeks after thyroidectomy
(AST: 67 U/L, ALT: 126 U/L, total bilirubin 1.9 mg/dL) and
demonstrated near-complete resolution 2 months from hos-
pital discharge. He was lost to follow up, and hence, no further
liver chemistries were obtained. Figure 1 summarizes liver
chemistry trends during the patient’s illness.
DISCUSSION
Cholestatic hepatitis represents a diagnostic challenge consid-
ering the broad differential diagnosis and the variability in
clinical presentation and severity. In the reported case, the
presence of weight loss, diarrhea, and atrial fibrillation
prompted early thyroid function testing to establish the di-
agnosis. Nevertheless, a thorough evaluation for viral hepatitis,
biliary disease, drug-induced or supplement-induced liver in-
jury, Wilson’s disease, hemochromatosis, autoimmune liver
pathologies, and cardiac diseasewas required before confirming
the diagnosis. Ferritin elevation was noted in the case as an
elevated acute-phase reactant rather than a manifestation of
iron overload. Severe cholestasis in hyperthyroidism could
occur, regardless of the concomitant presence of thyroid storm
or heart failure, as in our patient.8
Previous similar cases in the literature reported cholestatic liver
enzyme patterns (R factor,2) and mild ALT elevation (,100
U/L).9–14 Interestingly, our patient developed a mixed liver in-
jury pattern with peak ALT levels.10 times the upper limit of
normal. Although a rapid improvement in our patient’s cho-
lestasis occurred with methimazole and prednisone therapy,
complete resolution of jaundice occurred only 2 weeks after
definitive treatment with surgical thyroidectomy. The severity
of liver injury could pose a management challenge, given the
need to balance the risks of worsening hepatotoxicity by using
antithyroid therapies to treat the underlying primary
process.10,15,16
Both methimazole/carbimazole and propylthiouracil have
risks of cholestatic liver injury but overall low liver failure
risks. In the setting of existing liver dysfunction, these risks
may be increased and should be carefully weighed against
these therapies’ benefits. Closer monitoring of liver function
in patients with existing liver dysfunction receiving anti-
thyroid therapies may be necessary. RAI ablation may pre-
sent the preferred modality for treating Graves’ disease
patients with liver dysfunction, but further evidence is
Figure 1. (A) Liver enzyme trend since hospitalization and (B) serum total bilirubin trend since hospitalization.
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required.9,10,17,18 In our case, the management strategy
comprises lower dose methimazole therapy, followed by
surgical thyroidectomy because of patient preference.
Suggested mechanisms for liver injury in hyperthyroidism
include mitochondrial structural disruption and apoptotic
activation of hepatocytes by triiodothyronine (T3).19 Clinical
correlates associated with liver dysfunction in Graves’ dis-
ease include higher free T3 levels, age greater than or equal to
45, and thyrotropin receptor antibody concentration. De-
spite the absence of all 3 correlates in our patient, significant
liver injury was present. In conclusion, Graves’ disease
should be entertained on the differential diagnosis for cho-
lestatic hepatitis, even in the absence of thyroid storm.
Treatment choice may prove to be challenging, and further
studies are required to corroborate the safety of RAI in this
setting and to identify mechanisms of liver injury secondary
to hyperthyroidism.
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